Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows

Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows
People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination of Seattle Genetics' tucatinib plus standard trastuzumab and Xeloda (capecitabine), results from a Phase 2 trial show. The triple combination was also significantly better than a trastuzumab-Xeloda combo at delaying death or disease progression in people with brain metastasis at baseline. Seattle Genetics plans to submit these data to the U.S. Food and Drug Administration (FDA) to seek approval of the triple combo treatment for this patient population. “The addition of tucatinib to the commonly used doublet of trastuzumab and capecitabine represents a potential significant clinical advance for patients with metastatic HER2-positive breast cancer, importantly, including those with brain metastases,” Roger Dansey, MD, chief medical officer at Seattle Genetics, said in a news release. About a fifth of breast cancers are driven by the protein HER2, which acts to send signals that drive excessive cell growth, and is associated with more aggressive cancers. For these patients, treatments such as trastuzumab and
Subscribe or to access all post and page content.